SynthesisPloS one2025
Prevalence and correlation of sarcopenia with Alzheimer's disease: A systematic review and meta-analysis.
Synthesis in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- How Pragmatic Are Sarcopenia Intervention Studies? A Systematic Review.Journal of cachexia, sarcopenia and muscle · 2026Pooled it
- Comprehensive Review of Anesthetic Strategies for Patients With Neurodegenerative Diseases.Medical science monitor : international medical journal of experimental and clinical research · 2026Review
- Integrated Analysis of Cerebral Small Vessel Disease and Facial Soft-Tissue Markers in the Alzheimer's Disease Continuum.Brain sciences · 2026Article
- Article
- From muscle to brain: the mediating effect of vitamin D in the relationship between muscle loss and cognitive function in Alzheimer's disease.Frontiers in aging neuroscience · 2026Article
- Sarcopenia in the Aging Process: Pathophysiological Mechanisms, Clinical Implications, and Emerging Therapeutic Approaches.International journal of molecular sciences · 2025Review
- Neural Cues and Genomic Clues: NGS Insights into Neurogenic Sarcopenia and Muscle Atrophy.International journal of molecular sciences · 2025Review
- Association between sleep characteristics and physical functioning in middle-aged and elderly adults: findings from Chinese cohorts.Aging clinical and experimental research · 2025Article
- Nutritional and physical pathways from feeding difficulty to sarcopenia in Alzheimer's dementia.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcopenia, which is defined by a decline in skeletal muscle mass and strength associated with aging, is common among older individuals and presents considerable health dangers. Alzheimer's disease (AD) is a prevalent degenerative brain condition linked to a decrease in cognitive function. The intersection of these conditions remains underexplored. The goal of this systematic review and meta-analysis was to establish the frequency of sarcopenia in individuals with AD and investigate the relationship between sarcopenia and AD.
methodsWe performed an extensive review of literature databases, including PubMed, Embase, Web of Science, and the Cochrane Library, through April 2024. The inclusion criteria included studies that provided data on the frequency of sarcopenia in patients with AD or that examined the odds ratios (ORs) associated with these comorbidities. R Studio (4.3.1) was utilized for conducting the statistical analyses.
resultsA total of 27 studies, comprising 3902 AD patients were included. In patients with AD, the combined occurrence of sarcopenia was 33.9%, with a confidence interval (CI) of 95%, ranging from 27.6% to 40.2%. Sarcopenia was found in 31.2% (95% CI: 0.223-0.402) and 41.9% (95% CI: 0.321-0.516) of patients with mild and moderate AD, respectively. The OR for the association between AD and sarcopenia was 2.670 (95% CI: 1.566-4.555), suggesting a robust correlation.
conclusionSarcopenia is highly prevalent in AD patients, highlighting the need for integrated care approaches to address both cognitive and physical health issues. Further research is needed to elucidate the pathophysiological links between AD and sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.